WASHINGTON — They are little-known lawyers and professionals — with almost no experience in health care. And yet they are poised to play an outsized role in the federal effort to bring down high prescription drug prices.
The five men and women are in line to take charge of the Federal Trade Commission — a role that will let them decide whether to investigate companies over potentially anti-competitive tactics, whether to block mergers or acquisitions, and whether to demand more information about secretive business practices.
About the Author Reprints
